동물 건강 시장 : 동물 유형별, 제품, 치료 용도별, 유통 채널별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Animal Health Market is projected to grow by USD 135.84 billion at a CAGR of 8.58% by 2032.

Animal Health Market Introduction

Animal health has become a strategic priority across food security, public health, companion animal care, animal welfare, and global trade. Verified guidance from WOAH, FAO, WHO, FDA, EMA, USDA, and national veterinary authorities shows that disease prevention, vaccination, diagnostics, responsible antimicrobial use, and biosecurity are now central to resilient animal health systems.

Demand is being shaped by rising pet ownership, higher animal protein consumption, intensified livestock production, aquaculture expansion, and greater awareness of zoonotic disease risks. The sector is moving from reactive treatment to preventive, data-enabled veterinary care that supports One Health outcomes across animals, people, and ecosystems.

Transformative Shifts in Animal Health

The animal health landscape is being transformed by stronger disease surveillance, tighter antimicrobial stewardship, and growing investment in preventive care. Regulatory frameworks in the United States and European Union have increased veterinary oversight of medically important antimicrobials, while WOAH standards continue to shape international biosecurity, disease notification, and trade-related animal health requirements.

At the same time, veterinary clinics, livestock producers, and animal health manufacturers are adopting connected diagnostics, cold-chain improvements, telehealth tools, and precision herd management. These shifts are increasing demand for vaccines, parasiticides, diagnostics, nutrition-linked health solutions, pharmacovigilance systems, and digital veterinary platforms that improve clinical decision-making and disease preparedness.

Cumulative Impact of Artificial Intelligence in Animal Health

Artificial intelligence is creating cumulative value across veterinary imaging, pathology support, disease forecasting, pharmacovigilance, clinic workflow automation, and livestock monitoring. AI-enabled tools can help clinicians identify patterns in radiographs, laboratory results, electronic medical records, and wearable data, improving triage and decision support when validated against clinical evidence.

In production animal health, AI supports early detection of lameness, respiratory disease, mastitis risk, heat stress, abnormal behavior, and feed efficiency issues. Its impact is strongest when combined with veterinary oversight, high-quality datasets, transparent validation, cybersecurity controls, and compliance with data privacy, animal welfare, and medical device expectations.

Key Regional Insights

Asia-Pacific is expanding through large livestock populations, aquaculture growth, rising companion animal spending, and continued disease-control priorities in China, India, Japan, Australia, South Korea, and Southeast Asian economies. North America remains a high-value animal health region supported by advanced veterinary infrastructure, pet insurance adoption, biologics innovation, diagnostic capacity, and strict antimicrobial oversight across companion animal and food animal care.

Latin America benefits from Brazil and Mexico's export-oriented livestock systems, vaccination programs, and growing demand for poultry, cattle, and companion animal health solutions. Europe is shaped by EU animal health law, sustainability policy, veterinary pharmacovigilance, animal welfare standards, and coordinated antimicrobial stewardship. The Middle East is investing in food security, import controls, camel and ruminant health, and modern veterinary services, while Africa remains focused on vaccination access, transboundary disease control, zoonotic disease surveillance, and the expansion of veterinary infrastructure.

Key Group Insights

ASEAN animal health demand is supported by poultry, swine, aquaculture, and companion animal growth, with disease control remaining essential for food security, export continuity, and biosecurity management. The GCC is prioritizing food security, camel and ruminant health, livestock import controls, and high-quality veterinary services in urban companion animal markets, reflecting the region's focus on resilient supply chains and preventive care.

The European Union leads on antimicrobial stewardship, animal welfare, pharmacovigilance, and regulatory harmonization under a coordinated animal health framework. BRICS economies combine large livestock bases, expanding aquaculture, zoonotic disease priorities, and rising pet care expenditure, while G7 markets drive innovation in biologics, diagnostics, veterinary services, digital health, and advanced regulatory compliance. NATO members increasingly view biosecurity, veterinary readiness, and protection of food systems as part of broader resilience planning.

Key Country Insights

The United States leads in veterinary biologics, companion animal services, diagnostics, pet insurance adoption, and regulatory modernization, while Canada emphasizes surveillance, food safety, antimicrobial stewardship, and livestock health programs. Mexico and Brazil remain important livestock markets, with Mexico linked closely to North American animal protein trade and Brazil especially influential in beef and poultry exports, vaccination, and herd health management.

The United Kingdom, Germany, France, Italy, and Spain combine mature veterinary networks with EU or aligned animal welfare, pharmacovigilance, and antimicrobial stewardship standards, while Russia maintains demand across livestock productivity, disease prevention, and companion care. China and India offer scale in production animals, aquaculture, vaccines, and pets; Japan, Australia, and South Korea emphasize premium companion animal care, biosecurity, diagnostics, preventive medicine, and advanced companion animal therapeutics.

Actionable Recommendations for Animal Health Leaders

Industry leaders should prioritize preventive health portfolios, including vaccines, diagnostics, parasiticides, biosecurity solutions, and disease monitoring tools. Commercial strategies should align with antimicrobial stewardship, veterinarian-led care, animal welfare expectations, and evidence-based claims that meet regulatory and pharmacovigilance requirements.

Organizations should also invest in regional manufacturing resilience, cold-chain reliability, supply-chain visibility, digital adoption, and partnerships with clinics, producers, universities, laboratories, and public agencies. AI initiatives must be clinically validated, explainable, secure, and integrated into veterinary workflows rather than positioned as replacements for professional judgment.

Research Methodology

This executive summary is based on triangulated secondary research from authoritative organizations, including WOAH, FAO, WHO, OECD, FDA, USDA, EMA, ECDC, EFSA, and national veterinary and agriculture agencies. The analysis emphasizes verified regulatory developments, disease-control priorities, antimicrobial stewardship policies, documented production trends, and evidence-based animal health drivers.

The assessment combines policy review, value-chain mapping, product category analysis, regional benchmarking, disease surveillance interpretation, and validation against publicly available clinical, trade, and regulatory evidence. Qualitative insights are framed conservatively to avoid unsupported market-size, market-share, or growth-rate claims.

Conclusion

Animal health is moving toward prevention, surveillance, stewardship, and digitally enabled veterinary care. The sector's momentum is linked to pet humanization, livestock productivity, aquaculture growth, food safety, disease preparedness, and the global One Health agenda.

Organizations that combine scientific credibility, regulatory discipline, access-focused distribution, resilient supply chains, and responsible AI adoption will be best positioned. Long-term success will depend on delivering measurable animal welfare, veterinary efficiency, public health, food security, and producer productivity outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Animal Health Market, by Animal Type

• 7.1. Companion Animals
  • 7.1.1. Cats
  • 7.1.2. Dogs
• 7.2. Livestock
  • 7.2.1. Aquaculture
  • 7.2.2. Cattle
  • 7.2.3. Poultry
  • 7.2.4. Swine

8. Animal Health Market, by Product

• 8.1. Diagnostics
  • 8.1.1. Immunological Diagnostics
  • 8.1.2. Molecular Diagnostics
• 8.2. Feed Additives
  • 8.2.1. Enzymes
  • 8.2.2. Prebiotics
  • 8.2.3. Probiotics
• 8.3. Parasiticides
  • 8.3.1. Ectoparasiticides
  • 8.3.2. Endoparasiticides
• 8.4. Pharmaceuticals
  • 8.4.1. Branded
  • 8.4.2. Generics
• 8.5. Vaccines
  • 8.5.1. Killed Inactivated
  • 8.5.2. Live Attenuated
  • 8.5.3. Recombinant

9. Animal Health Market, by Therapeutic Application

• 9.1. Anti Infectives
  • 9.1.1. Antibiotics
  • 9.1.2. Antifungals
  • 9.1.3. Antivirals
• 9.2. Anti Inflammatories
  • 9.2.1. Corticosteroids
  • 9.2.2. NSAIDs
• 9.3. Antiparasitics
  • 9.3.1. Ectoparasiticides
  • 9.3.2. Endoparasiticides
• 9.4. Hormonal Therapeutics
  • 9.4.1. Growth Hormones
  • 9.4.2. Reproductive Hormones

10. Animal Health Market, by Distribution Channel

• 10.1. Online Stores
  • 10.1.1. Direct To Consumer Websites
  • 10.1.2. Third Party Platforms
• 10.2. Offline
  • 10.2.1. Chain Pharmacies
  • 10.2.2. Independent Pharmacies

11. Animal Health Market, by End User

• 11.1. Animal Owners
  • 11.1.1. Livestock Farmers
  • 11.1.2. Pet Owners
• 11.2. Feed Manufacturers
• 11.3. Veterinarians
  • 11.3.1. Large Animal Veterinarians
  • 11.3.2. Mixed Practice Veterinarians
  • 11.3.3. Small Animal Veterinarians

12. Animal Health Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Animal Health Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Animal Health Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Alivira Animal Health Limited
• 16.2. Alltech, Inc.
• 16.3. Anivive Lifesciences, Inc.
• 16.4. Boehringer Ingelheim International GmbH
• 16.5. Bova Holdings Limited by Vimian Group
• 16.6. Cargill, Incorporated
• 16.7. Ceva Sante Animale SA
• 16.8. Chr. Hansen Holding A/S
• 16.9. Colorado Serum Company
• 16.10. Covetrus, Inc.
• 16.11. Dechra Pharmaceuticals PLC
• 16.12. Dorwest Herbs Ltd.
• 16.13. Domes Pharma Group
• 16.14. Elanco Animal Health Incorporated
• 16.15. Heska Corporation
• 16.16. HIPRA, S.A.
• 16.17. Huvepharma AD
• 16.18. IDEXX Laboratories, Inc.
• 16.19. INVETRO Animal Health Pty Ltd
• 16.20. Kemin Industries, Inc.
• 16.21. knoell Animal Health Ltd.
• 16.22. Koninklijke DSM N.V.
• 16.23. Mars, Incorporated
• 16.24. Medfiles Group
• 16.25. Merck & Co., Inc.
• 16.26. Neogen Corporation
• 16.27. Phibro Animal Health Corporation
• 16.28. Vetoquinol S.A.
• 16.29. Virbac S.A.
• 16.30. Zoetis Inc.